
Largest-ever merger of black holes forms one 225 times the mass of the sun, astronomers say
Two black holes combined to make the massive one, according to the LIGO-Virgo-KAGRA Collaboration, an international group that uses gravitational waves to detect black hole mergers and who identified the event. Gravitational waves occur when there are minute distortions in spacetime, caused by events like black hole mergers, the group said in a news release.
One of the black holes was about 103 times the mass of the sun. The other was about 137 times it. These large black holes may have been formed by even earlier mergers, Professor Mark Hannam, from Cardiff University and a member of the LIGO Scientific Collaboration, said in a news release.
Even within the merger, the black holes are rapidly spinning, scientists said. Their rotation speed is about 400,000 Earth's rotation speed, the collaboration said in a graphic. They are moving at about 80% to 90% of the maximum possible speed.
"The black holes appear to be spinning very rapidly — near the limit allowed by Einstein's theory of general relativity," said Dr. Charlie Hoy, a gravitational-wave astrophysicist, LIGO member and postdoctoral research fellow at the University of Portsmouth, in the news release. "That makes the signal difficult to model and interpret."
The massive black hole has been dubbed GW231123. Its unusual size and behavior is challenging scientists' understanding of black hole formation, Hannam said. Previously, the largest known black hole that came from a merger was about 140 times the mass of the sun.
GW231123's discovery is also opening doors for new avenues of research, astronomers said. The behavior and size of the black hole "pushes the limits of" current theoretical models and existing gravitational-wave detection technology, the LIGO-Virgo-KAGRA Collaboration said.
"It will take years for the community to fully unravel this intricate signal pattern and all its implications," Dr. Gregorio Carullo, a LIGO member and an assistant professor at the University of Birmingham's Institute for Gravitational Wave Astronomy, said in a statement. "Despite the most likely explanation remaining a black hole merger, more complex scenarios could be the key to deciphering its unexpected features. Exciting times ahead!"
The black hole was discovered in November 2023, during an observation period by the LIGO-Virgo-KAGRA Collaboration. The observation period began in May 2023, and the first part of the period ended in January 2024.
More information about GW231123 and other black holes discovered by the collaboration will be presented this month at the 24th International Conference on General Relativity and Gravitation (GR24) and the 16th Edoardo Amaldi Conference on Gravitational Waves, two conferences presented jointly in Glasgow, Scotland. Data from the observation window will be published later in the summer. The data used to detect and study the massive black hole will also be made available for other researchers to use, the collaboration said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
"Over the moon!" — Rare and endagered Red Panda twins born at Island zoo
An Isle of Wight zoo has said it is "over the moon" following the birth of rare Red Panda twin cubs. As the mammals are an endangered species, their arrival marks a significant moment for conservation efforts. The cubs were born at Amazon Word on June 17 to mum Xaio and dad Flint. As the cubs are still young and there is always a risk, the zoo has kept the news under wraps — until now. A spokesperson said: "Xiao has done such a fantastic job so far, we are all so proud of her and Flint for helping us play our role as a vital Education and Conservation Centre.." The cubs will remain hidden in the nest boxes until at least three months old and senior staff will continue to monitor the enclosure them via CCTV. Red Pandas are native to the Eastern Himalayas and south western China and are classified as endangered on the IUCN Red List. Their population is declining due to many factors, including habitat loss, human interference and poaching. The zoo said: "Xaio and Flint are part of an International Breeding Programme with zoo's in Europe so that together we can maintain a captive population of this amazing species." "You may not be able to see the cubs at this time but we hope if you can, you'll visit us this summer."
Yahoo
10 hours ago
- Yahoo
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA
We recently compiled a list of Alnylam Pharmaceuticals, Inc. stands eighth on our list and recently got approval for AMVUTTRA. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, with four FDA-approved drugs for rare genetic diseases. Recently, the company has made significant strides in treating transthyretin amyloidosis (ATTR), a progressive disease affecting the heart and nerves. In March 2025, the FDA approved AMVUTTRA (vutrisiran) to reduce cardiovascular death and hospitalizations in ATTR-CM patients, based on strong results from the HELIOS-B Phase 3 trial. The drug also received approval from the European Commission in June 2025. Long-term data (up to 42 months) continues to support its effectiveness in improving heart function and quality of life. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), considered one of the most undervalued stocks in the biotech sector, is advancing nucresiran (ALN-TTRsc04), a next-gen RNAi treatment for ATTR. Interim Phase 1 results show sustained TTR protein reduction (over 90% within 15 days), with potential for once- or twice-yearly dosing. The drug enters Phase 3 trials in 2025 through the TRITON-CM program, aiming for longer-lasting, more convenient treatment options. A close-up of a staff member counting pills in a pharmaceutical warehouse. Beyond ATTR, the business is expanding its pipeline with nine new investigational therapies by the end of 2025, including treatments for Huntington's disease, bleeding disorders, and type 2 diabetes. The company also initiated a landmark Phase 1 trial for ALN-HTT02 in Huntington's, marking its entry into neurotherapeutics. Platform upgrades are targeting improved delivery to organs like the brain, heart, and kidneys, enhancing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s ability to address both rare and common diseases. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
We recently compiled a list of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It's FDA-approved drug, Rezdiffra (resmetirom), is the first oral, liver-targeted thyroid hormone receptor-β agonist for MASH with moderate to advanced fibrosis (F2–F3). It is also being tested in compensated MASH cirrhosis patients. At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver stiffness and lowered the risk of liver decompensation in F4c patients. Notably, 51% of participants had a ≥25% reduction in liver stiffness, and 65% of those with baseline portal hypertension moved to lower-risk categories. Safety remained consistent with prior results. Looking ahead, the MAESTRO-NASH OUTCOMES trial, expected to read out in 2027, will evaluate Rezdiffra's ability to reduce liver-related events in compensated cirrhosis patients. Meanwhile, regulatory momentum continues: the EMA's CHMP issued a positive opinion in June 2025, with potential EU approval expected by August. Rezdiffra would then be the first MASH treatment approved in both the U.S. and Europe. A healthcare professional wearing a health communications device discussing patient data with a colleague. Further solidifying its position, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) secured a new U.S. patent for Rezdiffra's dosing rights in July 2025, enhancing its intellectual property and global commercialization strategy. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data